tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Dogwood reports Q3 EPS ($8.20) vs ($2.05) last year
PremiumThe FlyDogwood reports Q3 EPS ($8.20) vs ($2.05) last year
28d ago
Dogwood Therapeutics Announces Business Combination Plans
Premium
Company Announcements
Dogwood Therapeutics Announces Business Combination Plans
2M ago
Dogwood to present on Halneuron pain research program
Premium
The Fly
Dogwood to present on Halneuron pain research program
2M ago
Dogwood secures royalty free license to develop, commercialize SP16
PremiumThe FlyDogwood secures royalty free license to develop, commercialize SP16
2M ago
Buy Rating for Dogwood Therapeutics: Promising Phase 2b Study Results and Strategic Financial Positioning
Premium
Ratings
Buy Rating for Dogwood Therapeutics: Promising Phase 2b Study Results and Strategic Financial Positioning
4M ago
Dogwood Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Dogwood Therapeutics Reports Q2 2025 Financial Results
4M ago
Promising Growth Potential for Dogwood Therapeutics with Halneuron’s Development and Strong Financial Position
PremiumRatingsPromising Growth Potential for Dogwood Therapeutics with Halneuron’s Development and Strong Financial Position
7M ago
Buy Rating for Dogwood Therapeutics Driven by Promising Clinical Developments and Strong Financial Outlook
Premium
Ratings
Buy Rating for Dogwood Therapeutics Driven by Promising Clinical Developments and Strong Financial Outlook
7M ago
Dogwood Therapeutics Reports Progress in Pain Treatment Trials
Premium
Company Announcements
Dogwood Therapeutics Reports Progress in Pain Treatment Trials
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100